Uncovering the SUMOylation and ubiquitylation crosstalk in human cells using sequential peptide immunopurification

Nature Communications

Volumn 8, Issue , 2017, Pages

  Lamoliatte, Frédéric ^a,b   McManus, Francis P ^a   Maarifi, Ghizlane ^c   Chelbi Alix, Mounira K ^c   Thibault, Pierre ^a,b  

^a INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; DEUBIQUITINASE; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEASOME; SUMO PROTEIN; UBIQUITIN; PEPTIDE; PROTEIN;

CELLS AND CELL COMPONENTS; ENZYME ACTIVITY; GENE EXPRESSION; IMMUNE SYSTEM; INHIBITOR; PEPTIDE; PROTEIN; PROTEOMICS;

ARTICLE; CELL NUCLEUS INCLUSION BODY; HEK293 CELL LINE; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; PROTEIN MOTIF; PROTEIN PURIFICATION; PROTEOMICS; QUANTITATIVE ANALYSIS; SUMOYLATION; UBIQUITINATION; AFFINITY CHROMATOGRAPHY; CHEMISTRY; EVALUATION STUDY; GENETICS; METABOLISM; PROCEDURES; PROTEIN ANALYSIS;

AMINO ACID MOTIFS; CHROMATOGRAPHY, AFFINITY; HEK293 CELLS; HUMANS; PEPTIDES; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN INTERACTION MAPS; PROTEINS; PROTEOLYSIS; SUMOYLATION; UBIQUITIN; UBIQUITINATION;

EID: 85010376071     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms14109     Document Type: Article

References (53)

1. Geoffroy, M.-C. & Hay, R. T. An additional role for SUMO in ubiquitinmediated proteolysis. Nat. Rev. Mol. Cell. Biol. 10, 564-568 (2009).
2. Johnson, E. S. Protein modification by SUMO. Annu. Rev. Biochem. 73, 355-382 (2004).
3. Matunis, M. J., Coutavas, E. & Blobel, G. A novel ubiquitin-like modification modulates the partitioning of the Ran-GTPase-Activating protein RanGAP1 between the cytosol and the nuclear pore complex. J. Cell. Biol. 135, 1457-1470 (1996).
4. Melchior, F. SUMO-nonclassical ubiquitin. Annu. Rev. Cell. Dev. Biol. 16, 591-626 (2000).
5. Saitoh, H. & Hinchey, J. Functional heterogeneity of small ubiquitin-related protein modifiers SUMO-1 versus SUMO-2/3. J. Biol. Chem. 275, 6252-6258 (2000).
6. Seeler, J.-S. & Dejean, A. Nuclear and unclear functions of SUMO. Nat. Rev. Mol. Cell. Biol. 4, 690-699 (2003).
7. Rodriguez, M. S., Dargemont, C. & Hay, R. T. SUMO-1 conjugation in vivo requires both a consensus modification motif and nuclear targeting. J. Biol. Chem. 276, 12654-12659 (2001).
8. Hietakangas, V. et al. PDSM, a motif for phosphorylation-dependent SUMO modification. Proc. Natl Acad. Sci. USA 103, 45-50 (2006).
9. Hay, R. T. Decoding the SUMO signal. Biochem. Soc. Trans. 41, 463-473 (2013).
10. Liang, Y. C. et al. SUMO5, a novel poly-SUMO isoform, regulates PML nuclear bodies. Sci. Rep. 6, 26509 (2016).
11. Creton, S. & Jentsch, S. SnapShot: The SUMO system. Cell 143, 848-848.e841 (2010).
12. Weisshaar, S. R. et al. Arsenic trioxide stimulates SUMO-2/3 modification leading to RNF4-dependent proteolytic targeting of PML. FEBS Lett. 582, 3174-3178 (2008).
13. Uzunova, K. et al. Ubiquitin-dependent proteolytic control of SUMO conjugates. J. Biol. Chem. 282, 34167-34175 (2007).
14. Udeshi, N. D. et al. Methods for quantification of in vivo changes in protein ubiquitination following proteasome and deubiquitinase inhibition. Mol. Cell. Proteomics 11, 148-159 (2012).
15. Kim, W. et al. Systematic and quantitative assessment of the ubiquitin-modified proteome. Mol. Cell. 44, 325-340 (2011).
16. Galisson, F. et al. A novel proteomics approach to identify SUMOylated proteins and their modification sites in human cells. Mol. Cell. Proteomics 10, 004796 (2011).
17. Lamoliatte, F. et al. Large-scale analysis of lysine SUMOylation by SUMO remnant immunoaffinity profiling. Nat. Commun. 5, 5409 (2014).
18. Tammsalu, T. et al. Proteome-wide identification of SUMO2 modification sites. Sci. Signal. 7, rs2 (2014).
19. Impens, F., Radoshevich, L., Cossart, P. & Ribet, D. Mapping of SUMO sites and analysis of SUMOylation changes induced by external stimuli. Proc. Natl Acad. Sci. USA 111, 12432-12437 (2014).
20. Hendriks, I. A., DSouza, R. C. J., Yang, B., Verlaan-de Vries, M. & Mann, M. Vertegaal ACO. Uncovering global SUMOylation signaling networks in a site-specific manner. Nat. Struct. Mol. Biol. 21, 927-936 (2014).
21. Hendriks, I. A., DSouza, R. C., Chang, J.-G. & Mann, M. Vertegaal ACO. system-wide identification of wild-Type SUMO-2 conjugation sites. Nat. Commun. 6, 7289 (2015).
22. Batth, T. S., Francavilla, C. & Olsen, J. V. Off-line high-pH reversed-phase fractionation for in-depth phosphoproteomics. J. Proteome. Res. 13, 6176-6186 (2014).
23. Xiao, Z. et al. System-wide analysis of SUMOylation dynamics in response to replication stress reveals novel small ubiquitin-like modified target proteins and acceptor lysines relevant for genome stability. Mol. Cell. Proteomics 14, 1419-1434 (2015).
24. Bursomanno, S. et al. Proteome-wide analysis of SUMO2 targets in response to pathological DNA replication stress in human cells. DNA. Repair. (Amst). 25, 84-96 (2015).
25. Hendriks, I. A., Treffers, L. W., Verlaan-de Vries, M., Olsen, J. V. & Vertegaal, A. C. O. SUMO-2orchestrates chromatin modifiers in response to DNA damage. Cell Rep. 10, 1778-1791 (2015).
26. Matic, I. et al. Site-specific identification of SUMO-2 targets in cells reveals an inverted SUMOylation motif and a hydrophobic cluster SUMOylation motif. Mol. Cell. 39, 641-652 (2010).
27. Schimmel, J. et al. Uncovering SUMOylation dynamics during cell-cycle progression reveals FoxM1 as a key mitotic SUMO target protein. Mol. Cell. 53, 1053-1066 (2014).
28. Sohn, S.-Y., Bridges, R. G. & Hearing, P. Proteomic analysis of ubiquitin-like posttranslational modifications induced by the adenovirus E4-ORF3 protein. J. Virol. 89, 1744-1755 (2015).
29. Hendriks, I. A. & Vertegaal, A. C. A comprehensive compilation of SUMO proteomics. Nat. Rev. Mol. Cell. Biol. 17, 581-595 (2016).
30. Chou, M. F. & Schwartz, D. Biological sequence motif discovery using motif-x. Curr. Protoc. Bioinformatics Chapter 13, Unit 13, 15-24 (2011).
31. Bernier-Villamor, V., Sampson, D. A., Matunis, M. J. & Lima, C. D. Structural basis for E2-mediated SUMO conjugation revealed by a complex between ubiquitin-conjugating enzyme Ubc9 and RanGAP1. Cell 108, 345-356 (2002).
32. Udeshi, N. D. et al. Refined preparation and use of anti-diglycine remnant (K-e-GG) antibody enables routine quantification of 10, 000 s of ubiquitination sites in single proteomics experiments. Mol. Cell. Proteomics 12, 825-831 (2013).
33. Zhao, Y. et al. A TFTC/STAGA module mediates histone H2A and H2B deubiquitination, coactivates nuclear receptors, and counteracts heterochromatin silencing. Mol. Cell. 29, 92-101 (2008).
34. Wright, D. E. & Kao, C.-F. (Ubi)quitin the h2bit: recent insights into the roles of H2B ubiquitylation in DNA replication and transcription. Epigenetics 10, 122-126 (2015).
35. Pan, J. et al. USP37 directly deubiquitinates and stabilizes c-Myc in lung cancer. Oncogene 34, 3957-3967 (2015).
36. Finkbeiner, E., Haindl, M., Raman, N. & Muller, S. SUMO routes ribosome maturation. Nucleus 2, 527-532 (2011).
37. Wilson, V. G. SUMO Regulation of Cellular Processes (Springer, 2009).
38. Kadlckova, J., Holecek, M., Safranek, R., Tilser, I. & Kessler, B. M. Effects of proteasome inhibitors MG132, ZL3VS and AdaAhx3L3VS on protein metabolism in septic rats. Int. J. Exp. Pathol. 85, 365-371 (2004).
39. Maroui, M. A. et al. Requirement of PML SUMO interacting motif for RNF4-or arsenic trioxide-induced degradation of nuclear PML isoforms. PLoS ONE 7, e44949 (2012).
40. Tatham, M. H. et al. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat. Cell. Biol. 10, 538-546 (2008).
41. Lallemand-Breitenbach, V. et al. Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11 S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation. J. Exp. Med. 193, 1361-1371 (2001).
42. Lallemand-Breitenbach, V. et al. Arsenic degrades PML or PML-RARalpha through a SUMO-Triggered RNF4/ubiquitin-mediated pathway. Nat. Cell. Biol. 10, 547-555 (2008).
43. Sun, H. & Hunter, T. Poly-small ubiquitin-like modifier (PolySUMO)-binding proteins identified through a string search. J. Biol. Chem. 287, 42071-42083 (2012).
44. Dengjel, J. et al. Identification of autophagosome-Associated proteins and regulators by quantitative proteomic analysis and genetic screens. Mol. Cell. Proteomics 11, 014035 (2012).
45. Trost, M. et al. The phagosomal proteome in interferon-gamma-Activated macrophages. Immunity 30, 143-154 (2009).
46. Dieude, M. et al. The 20 S proteasome core, active within apoptotic exosomelike vesicles, induces autoantibody production and accelerates rejection. Sci. Transl. Med. 7, 318ra200 (2015).
47. Wang, Z. G. et al. PML is essential for multiple apoptotic pathways. Nat. Genet. 20, 266-272 (1998).
48. Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 26, 1367-1372 (2008).
49. Nock, R. & Nielsen, F. On weighting clustering. IEEE. Trans. Pattern. Anal. Mach. Intell. 28, 1223-1235 (2006).
50. Kanshin, E., Kubiniok, P., Thattikota, Y., DAmours, D. & Thibault, P. Phosphoproteome dynamics of Saccharomyces cerevisiae under heat shock and cold stress. Mol. Syst. Biol. 11, 813 (2015).
51. Kumar, L. & E Futschik, M. Mfuzz: A software package for soft clustering of microarray data. Bioinformation 2, 5-7 (2007).
52. Szklarczyk, D. et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 43, D447-D452 2015
53. Bolte, S. & Cordelieres, F. P. A guided tour into subcellular colocalization analysis in light microscopy. J. Microsc. 224, 213-232 (2006).